This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit August 22, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  

 


SOCIETY NEWS

Now Accepting Abstracts for CEOT 2015
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

AST
Feb. 5-7, 2015 
Sheraton Wild Horse Pass – Chandler, Arizona

Share your research with experts in transplantation. Submit your basic, clinical or translational abstract now! Make plans to attend this high-energy, intimate meeting where expert clinicians, leading diagnosticians, and world class scientists will address the field’s cutting edge challenges together with an engaged audience. This year’s CEOT will feature sessions on:
  • A Critical Review of Cell Therapies
  • Whatever Happened to Gene Therapy?
  • Organ Repair and Regeneration, and Organ Generation
  • Drug Development and Rediscovering Pathways
Click here to submit your basic, clinical or translational abstract.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




UPCOMING EVENTS IN TRANSPLANTATION


Register Early to Receive Discounted Rate!
AST
ESOT + AST Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Madrid, Spain

Register by Sept. 7 to take advantage of early registration and a discounted rate. Join the ESOT and AST in beautiful Madrid, Spain as together we explore:
  • New Options to Improve Immunosuppressive Therapy Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
  • Novel Diagnostics
    Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
  • Novel Targets for Immunosuppression B-cells, Plasma Cells and Complement
  • Personalized Medicine: Technique and Technology
    Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics and Mixed Chimerism
  • Cellular Strategies to Optimize Long Term Outcomes
    T-regs, Mesenchymal Cells, Facilitator Cells
Click here to learn more about this enlightening meeting, or view the full program.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




TRANSPLANT NEWS


Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: Recommendations and future directions
American Journal of Transplantation
A consensus meeting was held in Vienna on Sept. 8–9, 2013, to discuss diagnostic and therapeutic challenges surrounding development of diabetes mellitus after transplantation. The International Expert Panel comprised 24 transplant nephrologists, surgeons, diabetologists and clinical scientists, which met with the aim to review previous guidelines in light of emerging clinical data and research. Recommendations from the consensus discussions are provided in this article. Although the meeting was kidney-centric, reflecting the expertise present, these recommendations are likely to be relevant to other solid organ transplant recipients.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


COMMITMENT TO CARE
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


HLA antibody detection with solid phase assays: Great expectations or expectations too great?
American Journal of Transplantation
Alloantibodies directed against HLA antigens, are a barrier to long-term solid organ allograft survival. The clinical impact of preformed, donor-directed HLA alloantibodies range from acceptable risk to unequivocal contraindication for organ transplantation. HLA antibodies are key factors that limit patient access to donor organs. Serological methods were once the only approach to identify HLA antigens and antibodies.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Child and family adjustment following pediatric solid organ transplantation: Factors to consider during the early years post-transplant
Pediatric Transplantation
Adjusting to life after transplant can be challenging to pediatric solid organ transplant recipients and their families. In this review, we discuss a number of important factors to consider during the first 2–3 years after transplant (defined as the "early years"), including transitioning from hospital to home, returning to physical activity, feeding and nutrition, school reentry, potential cognitive effects of transplant, family functioning, and QOL. We highlight steps that providers can take to optimize child and family adjustment during this period.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Avoiding stay in the intensive care unit after liver transplantation: A score to assign location of care
American Journal of Transplantation
Select liver transplantation (LT) recipients in our program are transferred from operating room to postanesthesia care unit for recovery and extubation with transfer to the ward, completely eliminating an intensive care unit (ICU) stay. Developing a reliable method to determine patients suitable for fast-tracking would be of practical benefit to centers considering this practice. The aim of this study was to create a fast-tracking probability score that could be used to predict successful assignment of care location after LT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation
Transplantation
Incompatible live donor kidney transplantation is associated with an increased rate of antibody-mediated rejection (AMR) and subsequent transplant glomerulopathy. For patients with severe, oliguric AMR, graft loss is inevitable without timely intervention. This study reviewed their experience rescuing kidney allografts with this severe AMR phenotype by using splenectomy alone (n=14), eculizumab alone (n=5), or splenectomy plus eculizumab (n=5), in addition to plasmapheresis.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Indicators of treatment responsiveness to rituximab and plasmapheresis in antibody-mediated rejection after kidney transplantation
Transplantation
Treatment of patients with antibody-mediated rejection (AMR) after kidney transplantation by rituximab and plasmapheresis is ambiguous. Because of its unknown efficiency and serious side effects, biomarkers, which are predictive for responsiveness to this treatment in AMR patients, are required. Twenty renal transplant patients were included in this retrospective study. Selection was based on Renal Index Biopsies, classified according to Banff within 3 months before treatment. Patients were categorized into responders (R) and nonresponders (NR) depending on whether they returned to dialysis within 6 months after initiation of rituximab treatment.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


The current state of intestine transplantation: Indications, techniques, outcomes and challenges
American Journal of Transplantation
Intestine transplantation is the least common form of organ transplantation in the United States and often deemed one of the most difficult. Patient and graft survival have historically trailed well behind other organ transplants. Over the past 5–10 years registry reports and single center series have demonstrated improvements to patient survival after intestinal transplantation that now match patient survival for those without life-threatening complications on parenteral nutrition. For various reasons including improvements in medical care of patients with intestinal failure and difficulty accessing transplant care, the actual number of intestine transplants has declined by 25 percent over the past 6 years.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Transplantation community sets a goal for increasing organ transplants over the next 5 years (AST)
Kidney transplantation in children (The New England Journal of Medicine)
Circulating levels of 25-hydroxyvitamin D and acute cellular rejection in kidney allograft recipients (Transplantation)
The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression (Clinical Transplantation)
Association between liver transplant center performance evaluations and transplant volume (American Journal of Transplantation)

Don't be left behind. Click here to see what else you missed.
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Aug. 15, 2014
Aug. 8, 2014
Aug. 5, 2014
July 25, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063